Anti-Inflammatory Effects of Tacalcitol (1,24 (R) (OH)2D 3, TV-02) in the Skin of TPA-Treated Hairless Mice

Journal of Dermatology

Volumn 31, Issue 3, 2004, Pages 200-217

  Sato, Hiroaki ^a   Nakayama, Yasunori ^a   Yamashita, Chizuru ^a   Uno, Hiroshi ^a  

^a TEIJIN LTD   (Japan)

Author keywords

Chemokine; Inflammation; Psoriasis; Tacalcitol; Vitamin D3

Indexed keywords

ACETIC ACID DERIVATIVE; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1; MYELOPEROXIDASE; TACALCITOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; DEGRANULATION; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; ENZYME ACTIVITY; FEMALE; FIBROBLAST; HAIR FOLLICLE; HAIR ROOT; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KERATINOCYTE; MACROPHAGE; MAST CELL; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; PSORIASIS; SKIN INFLAMMATION; STAINING;

EID: 1842636150     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2004.tb00657.x     Document Type: Article

References (55)

1. Schubert C, Christophers E: Mast cells and macrophages in early relapsing psoriasis, Arch Dermatol Res, 277: 352-358, 1985.
2. Ackermann L, Harvima IT: Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-α and their degranulation is associated with expression of ICAM-1 in the epidermis, Arch Dermatol Res, 290: 353-359, 1998.
3. Petersen LJ, Hansen U, Kristensen JK, Nielsen H, Skov PS, Nielsen HJ: Studies on mast cells and histamine release in psoriasis: the effect of ranitidine, Acta Derm Venereol, 78: 190-193, 1998.
4. Van De Kerkhof PC, Werfel T, Haustein UF, et al: Tacalcitol ointment in the treatment of psoriasis vulgaris: a multicentre, placebo-controlled, double-blind study on efficacy and safety, Br J Dermatol, 135: 758-765, 1996.
5. 3) for the treatment of psoriasis, Br J Dermatol, 134: 238-246, 1996.
6. 3 analogue (MC 903) in a double-blind study, Br J Dermatol, 119: 223-230, 1988.
7. Van De Kerkhof PC: Biological activity of vitamin D analogues in the skin, with special reference to antipsoriatic mechanisms, Br J Dermatol, 132: 675-682, 1995.
8. 3) on cutaneous inflammation, epidermal proliferation and keratinization in psoriasis: a placebo-controlled, double-blind study, Br J Dermatol, 131: 57-63, 1994.
9. 3) treatment of psoriasis: an immunohistological evaluation, Acta Derm Venereol, 77: 268-272, 1997.
10. 3 analogs, J Invest Dermatol Symp Proc, 1: 78-81, 1996.
11. Mommers JM, Castelijns FA, Seegers BA, et al: The effect of long-term treatment with tacalcitol on the psoriatic epidermis. A flow cytometric analysis, Br J Dermatol, 139: 468-471, 1998.
12. 3: a multiparameter flow cytometrical analysis of epidermal growth, differentiation and inflammation, Acta Derm Venereol Suppl, (Stockh) 75: 381-385, 1995.
13. 3 is a potent regulator of interleukin-1 induced interleukin-8 expression and production, Biochem Biophys Res Commun, 176: 1020-1026, 1991.
14. 3 analogue MC903 on secretion of interleukin-1 alpha (IL-1 alpha) and IL-8 by normal human keratinocytes and a human squamous cell carcinoma cell line (HSC-1), J Dermatol Sci, 7: 24-31, 1994.
15. Schon MP: Animal models of psoriasis-What can we learn from them?, J Invest Dermatol, 112: 405-410, 1999.
16. Mccullough JL, Weinstein GD, Ziboh VA: Cell kinetics in psoriasis: The use of animal and human skin models, in Maibach HI, Lowe NJ (eds): Models in Dermatology Vol. 1, Dermatology, Karger, Basel, 1985, pp 51-58.
17. Marks F, Furstenberger G, Kownatzeki E: Prostaglandin E-mediated mitogenic stimulation of mouse epidermis in vivo by divalent cation ionophore A 23187 and by tumor promoter 12-O-tetradecanoylphorbol-13-acetate, Cancer Res, 141: 696-702, 1981.
18. Gupta AK, Fisher GJ, Elder JT, et al: Topical cyclosporine A inhibits the phorbol ester induced hyperplastic inflammatory response but not protein kinase C activation in mouse epidermis, J Invest Dermatol, 93: 379-386, 1989.
19. 3 of induction of epidermal ornithine decarboxylase caused by 12-O-tetradecanoylphorbol-13-acetate and teleocidin B, Cancer Res, 44: 1387-1391, 1984.
20. 3, TV-02) inhibits phorbol ester-induced epidermal proliferation and cutaneous inflammation, and induces epidermal differentiation in mice, Arch Dermatol Res, 288: 656-663, 1996.
21. Bradley PP, Priebat DA, Christensen RD, Rothstein G: Measurement of cutaneous inflammation: Estimation of neutrophil content with an enzyme marker, J Invest Dermatol, 78: 206-209, 1982.
22. Gillitzer R, Berger R, Mielke V, Muller C, Wolff K, Stingl G: Upper keratinocytes of psoriatic skin lesions express high levels of NAP-1/IL-8 mRNA in situ, J Invest Dermatol, 97: 73-79, 1991.
23. Sticherling M, Bornscheuer E, Schroder JM, Christophers E: Localization of neutrophil-activating peptide-1/interleukin-8-immunoreactivity in normal and psoriatic skin, J Invest Dermatol, 96: 26-30, 1991.
24. Zlotnik A, Yoshie O: Chemokines: a new classification system and their role in immunity, Immunity, 12: 121-127, 2000.
25. Berger G, Goldberg A, Ophir D: The inferior turbinate mast cell population of patients with perennial allergic and nonallergic rhinitis, Am J Rhinol, 11: 63-66, 1997.
26. Wershil BK, Murakami T, Galli SJ: Mast cell-dependent amplification of an immunologically nonspecific inflammatory response. Mast cells are required for the full expression of cutaneous acute inflammation induced by phorbol 12-myristate 13-acetate, J Immunol, 140: 2356-2360, 1988.
27. Sato H, Ogino Y, Takagi H, et al: Pharmacological profiles of high-concentration (20 μg/g) tacalcitol ointment: effects on cutaneous inflammation, epidermal proliferation, and differentiation in mice, J Dermatol, 30: 510-524, 2003.
28. Wetzler C, Kampfer H, Stallmeyer B, Pfeilschifter J, Frank S: Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: prolonged persistence of neutrophils and macrophages during the late phase of repair, J Invest Dermatol, 115: 245-253, 2000.
29. Yin JL, Shackel NA, Zekry A, et al: Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for measurement of cytokine and growth factor mRNA expression with fluorogenic probes or SYBR Green I, Immunol Cell Biol, 79: 213-221, 2001.
30. Lewinsohn DM, Bargatze RF, Butcher EC: Leukocyte-endothelial cell recognition: evidence of a common molecular mechanism shared by neutrophils, lymphocytes, and other leukocytes, J Immunol, 138: 4313-4321, 1987.
31. Schon M, Denzer D, Kubitza RC, Ruzicka T, Schon MP: Critical role of neutrophils for the generation of psoriasiform skin lesions in flaky skin mice, J Invest Dermatol, 114: 976-983, 2000.
32. Hui QW, Robert CS: Overexpression of protein kinase C-alpha in the epidermis of transgenic mice results in striking alterations in phorbol ester-induced inflammation and COX-2, MIP-2 and TNF-alpha expression but not tumor promotion, J Cell Science, 112: 3497-3506, 1999.
33. Gillitzer R, Berger R, Mielke V, Muller C, Wolff K, Stingl G: Upper keratinocytes of psoriatic skin lesions express high levels of NAP-1/IL-8 mRNA in situ, J Invest Dermatol, 97: 73-79, 1991.
34. Sticherling M, Bornscheuer E, Schroder JM, Christophers E: Localization of neutrophil-activating peptide-1/interleukin-8-immunoreactivity in normal and psoriatic skin, J Invest Dermatol, 96: 26-30, 1991.
35. Debets R, Hegmans JP, Deleuran M, Hooft S, Benner R, Prens EP: Expression of cytokines and their receptors by psoriatic fibroblast. I. Altered IL-6 synthesis, Cytokine, 8: 70-79, 1996.
36. Duan H, Koga T, Kohda F, Hara H, Urabe K, Furue M: Interleukin-8-positive neutrophils in psoriasis, J Dermatol Sci, 26: 119-124, 2001.
37. Tuschil A, Lam C, Haslberger A, Lindley I: Interleukin-8 stimulates calcium transients and promotes epidermal cell proliferation, J Invest Dermatol, 99: 294-298, 1992.
38. Strieter RM, Kunkel SL, Elner VM, et al: Interleukin-8. A corneal factor that induces neovascularization, Am J Pathol, 141: 1279-1284, 1992.
39. Moller A, Lippert U, Lessmann D, et al: Human mast cells produce IL-8, J Immunol, 151: 3261-3266, 1993.
40. 3 analogue, OCT, on immunomodulatory function of keratinocytes and lymphocytes, Arch Dermatol Res, 291: 500-506, 1999.
41. 3 (tacalcitol), Br J Dermatol, 138: 63-70, 1998.
42. 3, Br J Pharmacol, 124: 1433-1438, 1998.
43. 3 with high activity for inducing epidermal differentiation but decreased hypercalcemic activity, J Dermatol, 17: 135-142, 1990.
44. 3 to induce keratinocyte differentiation, J Dermatol, 17: 707-709, 1990.
45. 2, Biochem Biophys Acta, 925: 156-163, 1987.
46. 3 receptors in human skin biopsies, J Clin Endocrinol Metab, 51: 1463-1465, 1980.
47. Babina M, Krautheim M, Grutzkau A, Henz BM: Human leukemic (HMC-1) mast cells are responsive to 1alpha, 25-dihydroxyvitamin D (3): selective promotion of ICAM-3 expression and constitutive presence of vitamin D (3) receptor, Biochem Biophys Res Commun, 273: 1104-1110, 2000.
48. 3 on the growth of human keratinocytes, J Dermatol, 17: 97-103, 1990.
49. Ohta T, Fukuoka M, Sato H, Komoriya K: Chemistry and pharmacology of tacalcitol, in Kragballe K (ed): Vitamin D in Dermatology, Marcel Dekker, Inc, New York, Basel, 2000, pp 285-297.
50. 3 downregulates IgE-mediated murine biphasic cutaneous reactions, Int Arch Allergy Immunol, 111: 71-76, 1996.
51. 3 on mast cell proliferation and A23187-induced histamine release, also accompanied by a decreased c-kit receptor, Arch Dermatol Res, 288: 709-715, 1996.
52. 3 enhances degranulation of mast cells, Mol Cell Endocrinol, 142: 49-55, 1998.
53. High-concentration TV-02 ointment clinical study group: Efficacy and safety of high-concentration TV-02 ointment in patients with psoriasis vulgaris.-A double-blind, right-to-left comparative study (phase III study)-, Nishinihon J Dermatol, 64: 105-119, 2002. (in Japanese)
54. Katayama I, Ohkawara A, Ohkido M, et al: High-concentration (20 mug/g) tacalcitol ointment therapy on refractory psoriasis vulgaris with low response to topical corticosteroids, Eur J Dermatol, 12: 553-557, 2002.
55. Miyachi Y, Ohkawara A, Ohkido M, et al: Long-term safety and efficacy of high-concentration (20 microg/g) tacalcitol ointment in psoriasis vulgaris, Eur J Dermatol, 12: 463-468, 2002.